The trial is designed primarily to confirm immunogenicity and safety of the vaccine in adults, with secondary objectives including preliminary evaluation of efficacy.
Ursula von der Leyen, President of the European Commission, said: "After intense negotiations, the European Commission has now concluded talks with a fifth pharmaceutical company, to enable rapid access to a vaccine against coronavirus for Europeans. Vaccine nationalism only helps the virus".
"The government has granted us permission to only manufacture the vaccine and stockpile it for future use", Serum Institute said on Sunday. The Financial Times reported Sunday that Trump was considering bypassing US regulatory standards to greenlight the vaccine before the November election. If it approves a vaccine for EUA and it proves unsafe or ineffective, it could dent public confidence in the agency.
Earlier today, Russian Federation formally reached out to the Indian government for partnership in the production of the COVID-19 vaccine candidate Sputnik-5. Phase-3 trials for Oxford-AstraZeneca vaccine are underway.
Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021.
EpiVacCorona: Russia’s second COVID-19 vaccine shows promise
The agency has said that the vaccine produces an immune response after double administration with an interval of 14-21 days. The companies revealed that the side effects of the latest vaccine BNT162b2 are less visible.
Zheng did not say how many workers had been inoculated, or which vaccine candidate was used, but said that the recipients included health workers and border officials.
Developing a vaccine is a complex and lengthy process, and the candidate must pass extensive field trials before it is cleared for human use. The need for a vaccine is rising with the number of global coronavirus deaths surpassing 800,000.
This isn't the first time the country has approved the use of an experimental vaccine.
UH Medical center is the first hospital system in Northeast Ohio and one of approximately 120 sites around the world that will collectively enroll up to 30,000 participants for the Phase 2/3 clinical trial.
COVAX is co-led by the GAVI vaccines alliance, the World Health Organization and the CEPI Coalition for Epidemic Preparedness Innovations and is created to guarantee equitable access globally to COVID-19 vaccines once they are developed and authorised for use.